Dazodalibep Expands Horizons With Phase II Sjögren’s Syndrome Data

Horizon Therapeutics plc’s acquisition of Viela Bio in early 2021 is showing signs of paying off as one of the key assets in that acquisition, dazodalibep, produced positive results in a Phase II study in Sjögren’s syndrome (SS).

The company announced 12 September that the Phase II trial, in SS patients with moderate-to-high systemic disease activity, met its primary endpoint of at least a five-point reduction in the European Alliance of Associations for Rheumatology Sjögren’s Syndrome Disease Activity Index (ESSDAI)